Randox Pharma Services Pushes the Boundaries of Biomarker Discovery

Randox has been supplying the world’s leading CRO’s, Pharmaceutical and Biotech companies for nearly three decades, and has unrivalled in-house technical know-how, whether in the development of new biomarker assays, companion diagnostics or the manufacture of the highest quality clinical diagnostic reagents.

Despite already supplying over 400 biomarker assays from their current product portfolio, Randox Pharma Services are investing to develop solutions for biomarker discovery, given their broad range of applications from the diagnosis, prognosis and monitoring of disease progression through to the monitoring of clinical responses to a therapeutic intervention and personalised medicine.

Currently biomarker discovery by mass spectrometry is an expensive and laborious method, with limitations in reproducibility and sensitivity due to the wide range of protein concentrations in plasma and extensive processing requirements. Biomarker validation and follow-on studies can also be impeded by a lack of available immuno-affinity reagents.

In response to these limitations, the recently developed QuantiPlasma Array from Randox is a monoclonal antibody microarray designed to assess the level of multiple proteins simultaneously in human plasma. Each kit contains 300 unique monoclonal antibodies, so by using the QuantiPlasma Array it is possible to directly assess the plasma proteome dynamics of normal and disease state plasma samples for identification of novel biomarkers in conjunction with Randox’s Biochip Array Technology analyser platform.

With such innovative solutions Randox Pharma Services is working to help meet the pressing need for biomarker discovery in a cost effective manner and ultimately enable their translation to new diagnostic solutions and improved healthcare.

For more information please visit the company article page.